Coronavirus News and Research

RSS

Study: SNAP benefits are critical to low-income Americans

When work requirements for a federal food safety-net program start again, many low-income Americans will lose benefits - and Black adults will be hardest hit, according to a study published today.

27 Jun 2020

Research shows ways to have a better day during a pandemic

It's entirely reasonable during a pandemic to feel more stressed, anxious, lonely and depressed than usual. Yet, despite the circumstances, some people are doing OK. Some people continue to feel love for others, gratitude for what they have and joy in the small things.

26 Jun 2020

Measuring air quality across London could help fight against COVID-19

Measuring air quality across London could help fight COVID-19 by providing a rapid means of deciding whether to reduce public transport movement - given strong links between exposure to air pollution and COVID-19 transmission, a new study reveals.

26 Jun 2020

Study finds 26% drop in the number of EMS calls since the start of COVID-19 pandemic

Since early March and the start of the COVID-19 pandemic in the U.S., 911 calls for emergency medical services have dropped by 26.1 % compared to the past two years, a new study led by a University at Buffalo researcher has found.

26 Jun 2020

Montana State researcher helps develop a better understanding of COVID-19 spread

How many people in the U.S. have had COVID-19? Using a database of information collected after the 2009 H1N1 outbreak, a Montana State University researcher is helping develop a better understanding of the spread of the novel coronavirus.

26 Jun 2020

Sweeps of homeless camps run counter to COVID guidance and pile on health risks

Melody Lewis lives like a nomad in the heart of downtown. Poking her head out of her green tent on a recent June day, the 57-year-old pointed a few blocks away to the place where city crews picked up her tent from a sidewalk median earlier this spring and replaced it with landscaping rocks, fencing and signs warning trespassers to keep out.

26 Jun 2020

HORIBA Medical white paper provides a review of hematology biomarkers for COVID-19 assessment

As experts in hematology HORIBA UK Ltd, Medical announces that the Company has published a white paper entitled, ‘COVID-19 screening, prognosis and severity assessment with biomarkers for management of patients’.

From HORIBA Medical 26 Jun 2020

BATM provides business and trading update

BATM, a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following business and trading update.

26 Jun 2020

Seniors in low-income housing live in fear of COVID infection

Davetta Brooks, 75, who has heart failure, a fractured hip and macular degeneration, is afraid. Conditions in her low-income senior building on Chicago's Near West Side — the Congressman George W. Collins Apartments — are "deplorable," she said.

26 Jun 2020

IQWiG supports initial assessment of coronavirus diagnostics

As a founding member, the Institute for Quality and Efficiency in Health Care (IQWiG) has been involved in EUnetHTA, a European network for Health Technology Assessment (HTA), since 2006.

26 Jun 2020

Antibody tests may give false hope of immunity, health experts warn

Amid the coronavirus pandemic, health experts warn against the use of antibody tests to determine if a person has immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An antibody test determines if a person developed antibodies against the infection due to past exposure.

26 Jun 2020

China to initiate phase 3 SARS-CoV-2 vaccine trial in UAE

Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China’s vaccine is the first one to proceed to phase III human trials.

26 Jun 2020

Chilblains and COVID-19

The current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily a respiratory infection, though the majority of cases are asymptomatic or mild disease. However, other manifestations are also being reported, such as gastrointestinal features, neurological signs, and skin symptoms. A new study published online in the journal JAMA Dermatology in June 2020 examines the possibility that chilblains could be a manifestation of COVID-19.

26 Jun 2020

Genes associated with SARS-CoV-2 human lung cell infection

Now, a new study published on the preprint server bioRxiv in June 2020 attempts to make sense of this data to identify viral genes that are explicitly expressed in the cells infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could help reveal new therapeutic targets.

26 Jun 2020

SARS-CoV-2 has been evolving for at least 7 years

The burning question is how novel viruses acquire the ability to recognize, bind to and enter human cells for the first time – whether this is dependent only on viral proteins recognizing host cell proteins, or adaptations in other viral processes that allow replication in a human host.

25 Jun 2020

Race, rurality play huge role in Georgia areas hardest hit by COVID-19

While counties in populous metropolitan Atlanta had the highest number of COVID-19 cases in the initial weeks following Georgia's first reported case, it was rural Southwest Georgia counties, with a higher number of black residents and lower number of ICU beds, experiencing the highest rates of infection and death per capita, investigators report.

25 Jun 2020

Entos Pharmaceuticals selects two lead DNA vaccine candidates for COVID-19

Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.

25 Jun 2020

Dysregulated inflammation in severe COVID-19

The continuing COVID-19 pandemic has so far caused 9.58 million cases and more than 488,000 deaths within just six months. The spectrum of disease is broad, from completely asymptomatic cases to critical illness ending in death. Now, a new paper by researchers from Yale University and published on the preprint server medRxiv* in June 2020 identifies an imbalance in immunological response that is linked to poor outcomes and early biomarkers that may help predict the course of the disease.

25 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

Biological therapy may decrease the risk of severe COVID-19

A recent observational study by Spanish researchers, currently available on the medRxiv preprint server, suggests that patients with immune-mediated diseases who receive biological therapy may have a lower risk for severe manifestations of coronavirus disease (COVID-19).

25 Jun 2020